## **Prostate 2023 Case Scenario**

45-year-old male who presented with abnormal DRE, nodule/mass on LT-hand side noted with normal seminal vesicle, with elevated PSA of 14.9 taken on 5/9/2021.

5/9/2021: Prostate core bx

1. Prostate, LT base: prostatic tissue with focal high grade prostatic intraepithelial neoplasia (HGPIN),
2. Prostate, LT mid: adenocarcinoma of prostate. GS= 7(4+3), involving 60% of tissue, 1 out of 2 cores involved by tumor,
3. Prostate, LT apex: adenocarcinoma of prostate. GS= 7(4+3), involving 90% of tissue, 2 out of 2 cores involved by tumor,
4. Prostate, RT base: benign prostatic tissue,
5. Prostate, RT mid: benign prostatic tissue,
6. Prostate RT apex: small fragment suspicious for prostatic adenocarcinoma:

8 cores total taken

5/10/21: MRI pelvis: Lesion in LT mid-gland to apex peripheral zone and transitional zone with features consistent with prostate cancer. No evidence of pelvic lymphadenopathy. No EPE and No SVI identified.

5/18/21: Robotic-assisted total radical prostatectomy

**Procedure:** Radical prostatectomy

**Histologic Type: A**denocarcinoma, mixed acinar and ductal type

**Histologic Grade**

**Grade Group and Gleason Score:** Grade group 2 (Gleason score 3 + 4)

**Percentage of Pattern 4 in Gleason Score 7:** 70%

**Percentage of Pattern 5:** 0%

**Tumor Quantitation:** Carcinoma present on 14 of 20 histologic

sections

**Extraprostatic Extension (EPE):** Not identified

**Urinary Bladder Neck Invasion:** Not identified

**Seminal Vesicle Invasion:** Not identified

**Margins:** Negative for carcinoma

**Treatment Effect on carcinoma:** No known presurgical therapy

**Lymphovascular Invasion:** Not identified

**Regional Lymph Nodes:** No nodes submitted

**Additional Pathologic Findings:** High grade prostatic intraepithelial neoplasia

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Worksheet | | | | | | | | | | | |
| Primary Site | **C619** |  | | | |  | | Clinical Grade | | 3 | |
| Histology | 8552/3 |  | | | |  | | Pathological Grade | | 3 | |
| RLN pos | 98 | RLN examined | | | | 00 | | Post Therapy Grade | |  | |
| Laterality | 0 | | | | | | | | | | |
| LVI | 0 | | | | | | | | | | |
| Tumor size clinical | 999 | | | | | | | | | | |
| Tumor size path | 999 | | | | | | | | | | |
| Tumor size summary | 999 | | | | | | | | | | |
| Stage Data items | | | | | | | | | | | |
| AJCC Stage | | | | | | | | | | | |
| Clinical T | cT2 | Pathological T | | | | pT2 | | Post-therapy T | |  | |
| cT Suffix |  | pT Suffix | | | |  | | pT Suffix | |  | |
| Clinical N | cN0 | Pathological N | | | | pNX | | Post-therapy N | |  | |
| cN Suffix |  | pN Suffix | | | |  | | pN Suffix | |  | |
| Clinical M | cM0 | Pathological M | | | | cM0 | | Post-therapy M | |  | |
| Clinical Stage | 2C | Pathological Stage | | | | 99 | | Post-therapy Stage | |  | |
|  | |  | | | | | |  | | | |
| Summary Stage 2018 | | | | 1-Localized | | | | |
| *EOD Primary Tumor* | | | | 250 | | | | |
| *EOD Lymph Regional Nodes* | | | | 000 | | | | |
| *EOD Mets* | | | | 00 | | | | |
| *Prostate Pathologic Extension* | | | | 300 | | | | |
| SSDI’s | | | | | | | | |
| Gleason Patterns Clinical | | | | | 43 | | | |
| Gleason Patterns Pathological | | | | | 34 | | | |
| Gleason Score Clinical | | | | | 07 | | | |
| Gleason Score Pathological | | | | | 07 | | | |
| Gleason Tertiary Pattern | | | | | X9 | | | |
| Number of Cores Positive | | | | | 03 | | | |
| Number of Cores Examined | | | | | 08 | | | |
| PSA | | | | | 14.9 | | | |
| Treatment | | | | | | | | | | | |
| Dx staging procedure | | | 02 | | | |  | | | |  |
| Surgery reason no rx | | | 0 | | | |  | | | |  |
| Surgical Approach at hospital | | | 1 | | | |  | | | |  |
| Surgery course | | | 1 | | | |  | | | |  |
| Surgery of primary site | | | 50 | | | |  | | | |  |
| Scope of RLN surgery | | | 00 | | | |  | | | |  |
| Surgery to other site | | | 00 | | | |  | | | |  |
| Cancer Status | | | 01 | | | | 12/22/2022 Urologist note PSA <0.014 | | | |  |